Pharmacoeconomic review report Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)

Preservative-free latanoprost (Monoprost) is available as a sterile ophthalmic solution in a single-dose container (50 mcg/mL). Health Canada approved Monoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OH) or open-angle glaucoma (OAG). The manufacturer is...

Full description

Bibliographic Details
Main Author: Canadian Agency for Drugs and Technologies in Health (author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Ottawa (ON) : CADTH 2018.
Series:Common drug review clinical review report.
Subjects:
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268506719
Description
Summary:Preservative-free latanoprost (Monoprost) is available as a sterile ophthalmic solution in a single-dose container (50 mcg/mL). Health Canada approved Monoprost for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OH) or open-angle glaucoma (OAG). The manufacturer is requesting that Monoprost be reimbursed as per the Health Canada-approved indication. The recommended dose is one drop in the affected eye(s) once daily. The manufacturer-submitted price was 20.54 per pack of 30 single-use containers, corresponding to a price of 0.68 per day.
Physical Description:1 online resource (37 pages) : illustrations
Bibliography:Includes bibliographical references.